Now showing items 1-10 of 10

    • Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. 

      Armstrong, AJ; Saad, F; Phung, D; Dmuchowski, C; Shore, ND; Fizazi, K; Hirmand, M; Forer, D; Scher, HI; Bono, JD (2017-06-15)
      BACKGROUND: In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased ...
    • Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. 

      Smith, MR; Saad, F; Rathkopf, DE; Mulders, PFA; de Bono, JS; Small, EJ; Shore, ND; Fizazi, K; Kheoh, T; Li, J; De Porre, P; Todd, MB; Yu, MK; Ryan, CJ (2017-07)
      In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists ...
    • DESNT: A Poor Prognosis Category of Human Prostate Cancer. 

      Luca, B-A; Brewer, DS; Edwards, DR; Edwards, S; Whitaker, HC; Merson, S; Dennis, N; Cooper, RA; Hazell, S; Warren, AY; CancerMap Group; Eeles, R; Lynch, AG; Ross-Adams, H; Lamb, AD; Neal, DE; Sethia, K; Mills, RD; Ball, RY; Curley, H; Clark, J; Moulton, V; Cooper, CS (2018-12)
      BACKGROUND: A critical problem in the clinical management of prostate cancer is that it is highly heterogeneous. Accurate prediction of individual cancer behaviour is therefore not achievable at the time of diagnosis leading ...
    • An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. 

      Sartor, O; Coleman, RE; Nilsson, S; Heinrich, D; Helle, SI; O'Sullivan, JM; Vogelzang, NJ; Bruland, Ø; Kobina, S; Wilhelm, S; Xu, L; Shan, M; Kattan, MW; Parker, C (2017-05-01)
      Background: Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, ...
    • Low-risk Prostate Cancer: Identification, Management, and Outcomes. 

      Moschini, M; Carroll, PR; Eggener, SE; Epstein, JI; Graefen, M; Montironi, R; Parker, C (2017-08)
      CONTEXT: The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing. OBJECTIVE: In this collaborative review article, we examine recent literature regarding low-risk ...
    • Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer. 

      Reis Ferreira, M; Khan, A; Thomas, K; Truelove, L; McNair, H; Gao, A; Parker, CC; Huddart, R; Bidmead, M; Eeles, R; Khoo, V; van As, NJ; Hansen, VN; Dearnaley, DP (2017-12-01)
      PURPOSE: To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa). METHODS AND MATERIALS: In a phase 1/2 study, ...
    • Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). 

      Mehra, N; Dolling, D; Sumanasuriya, S; Christova, R; Pope, L; Carreira, S; Seed, G; Yuan, W; Goodall, J; Hall, E; Flohr, P; Boysen, G; Bianchini, D; Sartor, O; Eisenberger, MA; Fizazi, K; Oudard, S; Chadjaa, M; Macé, S; de Bono, JS (2018-09)
      BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as ...
    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 

      Seibert, TM; Fan, CC; Wang, Y; Zuber, V; Karunamuni, R; Parsons, JK; Eeles, RA; Easton, DF; Kote-Jarai, Z; Al Olama, AA; Garcia, SB; Muir, K; Grönberg, H; Wiklund, F; Aly, M; Schleutker, J; Sipeky, C; Tammela, TL; Nordestgaard, BG; Nielsen, SF; Weischer, M; Bisbjerg, R; Røder, MA; Iversen, P; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, K-T; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Brenner, H; Cuk, K; Saum, K-U; Park, JY; Sellers, TA; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Clements, JA; Spurdle, A; Teixeira, MR; Paulo, P; Maia, S; Pandha, H; Michael, A; Kierzek, A; Karow, DS; Mills, IG; Andreassen, OA; Dale, AM; PRACTICAL Consortium* (2018-01-10)
      OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to ...
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MG; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, AT; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-01)
      BACKGROUND: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition ...
    • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 

      Scher, HI; Morris, MJ; Stadler, WM; Higano, C; Basch, E; Fizazi, K; Antonarakis, ES; Beer, TM; Carducci, MA; Chi, KN; Corn, PG; de Bono, JS; Dreicer, R; George, DJ; Heath, EI; Hussain, M; Kelly, WK; Liu, G; Logothetis, C; Nanus, D; Stein, MN; Rathkopf, DE; Slovin, SF; Ryan, CJ; Sartor, O; Small, EJ; Smith, MR; Sternberg, CN; Taplin, ME; Wilding, G; Nelson, PS; Schwartz, LH; Halabi, S; Kantoff, PW; Armstrong, AJ (2016-04)
      Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to ...